Recent reports of local-anaesthetic (LA)-induced myotoxicity after peripheral nerve blocks have increased the interest in this less commonly known complication. Basic science evidence investigating LA-induced myotoxicity seems to demonstrate a pattern, but findings from human studies vary. This systematic review summarises the existing myotoxicity evidence and empirically examines its implications. Databases were searched for all in vitro animal and human studies evaluating LA-induced myotoxicity. Studies were stratified by design. Data sought included the model examined, LA used, injury mechanisms, nature of damage, and extent of recovery. For human studies, we also aimed to estimate prevalence and recovery rates. One hundred and fifteen studies, mainly animal and ophthalmic, were included. Myotoxicity risk factors included higher concentrations and prolonged exposure to LA, and use of bupivacaine. Injury mechanisms involved early and late aberrations to cytoplasmic calcium (Ca 2þ ) homeostasis by the sarcoplasmic reticulum Ca 2þ ATPase. Incidence in ophthalmic studies was 0.77% (392 of 50 618). Inflammatory changes within a few days after exposure marked the onset of myotoxicity, and myo-degeneration followed within the first week post-exposure. Time to recovery in human muscles ranged between 4 days to 1 yr. None/partial and complete recovery were observed in 61% and 38% of patients, respectively. Across all experimental models, skeletal muscles exposed to LA consistently display myotoxic effects. Evidence is robust in animal and ophthalmic studies, and displays a concerning signal with continuous adductor canal block use in human case reports. Exploring the clinical prevalence, severity, and risk-reducing strategies of myotoxicity should be prioritised.
The growing popularity of regional anaesthesia techniques has prompted interest into the investigation of localanaesthetic (LA)-induced tissue damage. 1 Myotoxicity caused by LA agents was first described by Brun 2 in striated muscles in 1959, and has continued to garner interest as a serious complication of peripheral nerve blocks. 3 Although thought to be a rare and subclinical adverse effect of LAs in humans, several cases of clinically important myotoxicity have been reported in the literature, mostly after retrobulbar blocks. 4, 5 Non-ophthalmic instances of myotoxicity in humans have previously been limited to a handful of case reports after interscalene nerve block 6 and trigger point injection. However, we now have a reason to believe that the adductor canal block model may also place patients at risk of what we suspect is LAinduced myotoxicity. 7 Furthermore, an assortment of in vivo and in vitro studies has also offered information on the potential mechanisms of LA-induced myotoxicity, 8e10 the underlying histopathological changes in muscle fibres, 11, 12 and the varying clinical presentations. 6, 7 Notably, whilst basic science evidence consistently demonstrates a pattern of LAinduced myotoxicity, the findings of relevant human studies seem to vary between failure to detect any clinically important effect and dismissing myotoxicity altogether. 3 As a result, anaesthesiologists administering nerve blocks may not (i) identify LA-induced myotoxicity as a concern 9, 13 ; (ii) perceive it as related to regional anaesthesia interventions 3 ; or (iii)
report it as a complication, and thus, limiting our knowledge of the frequency and severity of this problem. Considering the potential relevance of these observations to the thousands of adductor canal blocks that are now done daily, we believe that a review of animal data to better understand mechanisms is warranted if we are to better study and understand the adductor canal block connection. Thus, the first objective of this review was to describe and summarise the recent in vitro, ex vivo, in vivo, and human evidence surrounding LA-induced myotoxicity to improve awareness on the topic. The second objective was to analyse empirically the implications of this evidence on the future of regional anaesthesia clinical practice.
Methods

Eligibility criteria
All human, animal, and in vitro studies examining the effect of LA intervention on muscle or myoblastic tissue were considered. Studies were excluded if the effects of LAs were evaluated exclusively on non-muscular tissue. Published reports describing any LA intervention for its implication in causing potential myotoxicity, or an inflammatory myopathy, were sought. Both quantitative and qualitative designs were considered, and studies across all levels of evidence 14 were eligible. No language restrictions were placed on inclusion criteria, and all non-English reports were translated using an online translator. For studies involving human and animal subjects, inclusion was limited to regional anaesthetic techniques.
Literature search
An evidence-based medicine librarian (L.B.) created a systematic search strategy for the US National Library of Medicine database (MEDLINE), Excerpta Medica database (Embase), Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Database of Systematic Reviews from inception until May 10, 2017 . The medical subject headings and keywords included in each search strategy related to myotoxicity, inflammatory myopathy, and LAs used for regional nerve blockade. The full search strategy for each respective database can be viewed in Supplementary Appendix A. The bibliographies of included citations were hand searched for additional studies that satisfied the inclusion criteria.
Selection of included studies
Two independent reviewers (N.H. and J.C.) screened the results from the electronic searches. The initial screen was based on title and abstract alone. The full-text versions of all potentially eligible articles were retrieved and further evaluated for inclusion by the two reviewers. The inclusion of a study was based on its relevance, or provision of new information on the topic, rather than level of evidence. In the case of disagreement between the two independent reviewers, a third reviewer (F.W.A.) evaluated the study, and a decision was reached by a consensus.
Data extraction
A standardised data-extraction form was created and piloted by an independent reviewer (N.H.). This form was subsequently used to evaluate the reported results from all studies included in this review. Two independent reviewers (N.H. and J.C.) performed data extraction in duplicate. In the case of a disagreement in data extraction, a third reviewer (F.W.A.) assessed the data in question and made the final decision. The dataextraction form for animal and in vitro studies collected information regarding the study design, year of publication, the animal model used, the cell line used, the muscle/cell of interest, nature of LAs provided, histological endpoint and timing of assessment, functional endpoint and timing of assessment, histological damage, and molecular damage. For human studies, the data-extraction form collected additional information regarding the total subjects included, type of nerve block performed, the surgical procedure performed, type of postoperative imaging, postoperative clinical signs and symptoms related to potential myotoxicity, clinical course of condition, the nature of recovery or muscle regeneration, and the time to recovery. The primary sources of descriptive and numerical data were text-based reported data. For data not presented textually and only reported in graphical form, extraction was carried out using a graph digitising software (GraphClick; Arizona Software, San Francisco, CA, USA).
Study classifications for data presentation
The literature evaluating LA-induced myotoxicity includes a variety of research methodologies. For the purposes of this
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review, we broadly classified all included studies into the study design categories of in vitro, ex vivo, in vivo, or human studies. Human reports were further classified according to the type of surgery being performed (orthopaedic, ophthalmologic, dental, or other), and the type of regional anaesthetic technique used.
To standardise the presentation, all in vitro, ex vivo, and in vivo studies had LA concentrations converted to an equivalent in millimolar. Studies were also classified according to the LA concentration examined into 'low' or 'high concentration', based on the nomenclature used in these studies. 15, 16 This was done to facilitate interpretability, as diverse classification of LA concentrations had been used. For in vitro studies, low concentration was defined as <1 mM, whilst high concentration was defined as !1 mM. For ex vivo and in vivo studies, low concentration was defined as <50 mM, whilst high concentration was defined as !50 mM.
Outcomes of interest
For human studies in specific, the two outcomes sought amongst the variety of procedures were the point prevalence of (i) myotoxicity, including the incidence of diplopia after cataract surgery with retrobulbar, peribulbar, periocular, and sub-Tenon's anaesthesia; and (ii) none/partial or complete patient recovery.
For the purpose of this review, myotoxicity after regional anaesthesia was defined as (i) occurrence of symptoms related to muscle damage, including muscle weakness/paralysis; (ii) occurrence of diplopia, ptosis, hypertropia, and hypotropia after cataract surgery; or (iii) enzymatic changes indicative of muscle damage, such as an elevated creatine phosphokinase (CPK) concentration.
The definition and extent of recovery by muscle regeneration differed between animal and human studies. For animal studies, the extent of recovery was classified as partial (0e25%), minimal (25e50%), or major (>50%). For human studies, the nature of recovery or regeneration was classified as being none/partial or complete. None/partial recovery was defined as a lack of return to baseline functional status after exposure to regional anaesthesia secondary to myotoxicity, or as a need for surgical/mechanical intervention to return to near-normal baseline function. In contrast, complete recovery was defined as a spontaneous return to baseline function without the use of surgical or mechanical intervention.
Data analysis
For the quantitative dichotomous outcomes of this review, a percent frequency with 95% confidence interval (CI) was calculated for the point prevalence of myotoxicity amongst the varied procedures; none/partial or complete patient recovery amongst the varied procedures; and diplopia after cataract surgery with retrobulbar, peribulbar, periocular, and sub-Tenon's anaesthesia.
Data management
All point-prevalence data were calculated using SPSS software (version 21.0; SPSS Inc., Chicago, IL, USA).
Empirical analysis
We also aimed to conduct an additional empirical analysis 17 of the probable implications of myotoxicity on the future of regional anaesthesia research and clinical practice. The systematic review, per se, will serve as the quantitative descriptive and analytic parts of the empirical analysis. 17 Subsequently, the results of this review will guide the theoretical part 17 of the empirical analysis that aims to interpret the potential impacts of myotoxicity.
Results
Our primary literature search yielded 549 citations. After duplicate citation removal, a total of 472 potentially eligible abstracts were identified, of which 256 did not meet the inclusion criteria. Of the remaining 216 abstracts, select studies were excluded for being exclusively performed in brain tissue, cardiac tissue, and neoplastic tissue. Studies reporting data on myoblastic tissue were included for their potential relevance. Thus, 115 unique articles were included after full-text revision. These included 106 with a single study design and 9 with multiple study designs. The full flow diagram for study inclusion can be seen in Figure 1 .
Results of experimental studies
In vitro studies
Study characteristics
A total of 29 1,13,15,18À43 in vitro studies satisfied the eligibility criteria and were included in this review. The key characteristics, including the source (whether human or animal), type of muscle or muscle group, cell type or cell line, and the key results of these in vitro studies, are summarised in Table 1 .
LA characteristics
The researchers evaluated the myotoxic effect of varying types and concentrations of LAs. The most commonly used LAs were bupivacaine (n¼20), 1,13, One study did not specify the LA concentration used. 18 
Myotoxic damage
All 29 studies evaluated the myotoxic effects of LAs in myoblastic tissue. Myotoxic damage was demonstrated in 28 of 29 studies. 1,13,15,19e43 The remaining study did not provide data on the myotoxic effects of cell-line incubation with LAs. 18 The nature and extent of the observed myotoxic effects varied according to LA type and concentration. A surge in myoblastic apoptosis is the sequela of LA exposure. 1,19e23,25e29 Apoptosis is triggered by increased inducing the formation of autophagosomes and leading to autophagic programmed cell death. 23 Studies of both low and high LA concentrations consistently showed that the severity of damage (apoptosis) is higher with increased concentration, 1,19e23,25e29 prolonged durations of exposure, 19,21,22,25e29 and bupivacaine formulations compared with ropivacaine. 25 At low concentrations, the proportion of cell death ranged from 16% to 95%, and occurred between 2 h and 11 days after exposure. At high concentrations, the proportion of cell death ranged from 60% to 100%, and occurred earlier, between 15 min and 11 days after exposure. 1,19e23,25,26,28 Apoptosis was similarly observed with both low and high concentrations of liposomal preparations of bupivacaine 26 and ropivacaine, 1,19e23,25e29 and microspheric preparations of bupivacaine 22 and lidocaine. 22 
Recovery
Recovery from myotoxic insult was not assessed by the in vitro studies included in this review.
Ex vivo studies
Study characteristics
The characteristics of the ex vivo studies included in the systematic review and the key results are summarised in Table 2 . Only one ex vivo study 45 performed in rats satisfied the eligibility criteria and was included in this qualitative review. The muscles isolated included the extensor digitorum longus 45 and soleus.
45
LA characteristics
The myotoxic effect of LAs was evaluated using i.m. injection with bupivacaine 5% suspension formulation. 
Myotoxic damage
Myotoxic damage consistent with observations from in vitro studies was reported in one study, 45 where high concentrations of bupivacaine led to brisk elevations of serum CPK in muscle tissue, within 60 min of injection.
45
Recovery
Recovery from myotoxic insult was not assessed by the ex vivo studies included in this review.
In vivo studies
Study characteristics
A total of 52 2,8e12,16,18e20,22,26,28,46e84 in vivo studies satisfied the eligibility criteria and were included. The key characteristics, including the animal source, type of muscle, or muscle group, and the key results of these studies, are summarised in Table 3 .
Myotoxic damage
Myotoxic damage has been consistently demonstrated with different muscle types, as shown in all 52 studies reviewed. 2,8e12,16,18e20,22,26,28,46e84 The effect observed on muscle fibres varied according to the concentration of LA used. In addition to damage at the cellular level, consistent with observations from in vitro studies, in vivo studies also displayed inflammatory and degenerative changes at the tissue level.
Muscle fibre inflammation
Regardless of concentration, the site of LA injection in muscle tissue became the site of a localised inflammatory response, 2 
Local anaesthetic characteristics
The regional anaesthesia techniques examined were dictated by the type of surgery performed: adductor canal block for knee surgery, 7,121 interscalene block for shoulder surgery, 6 Bier block for forearm and wrist/hand surgery, 87 and trigger point injection for myofascial pain management. 86 For eye surgery, the studies examined retrobulbar block, 7 and additional four were reported in a subsequent correspondence 121 ) out of 6121 (proportion: 0.14%; 95% CI: 0.05%, 0.23%) for orthopaedic procedures, 1 patient out of 1 (100%) for dental procedures, and 18 patients out of 18 (100%) for other experimental studies. For limb surgery, the most common symptoms included significant and acute onset Continued LA-induced myotoxicity in regional anaesthesia -829 and restrictive strabismus. 104 Enzymatic markers of myotoxicity were measureable, and particularly increased serum concentrations of CPK were observed in patients receiving i.m. LA injection.
47,120
Myotoxic damage appeared to occur independent of needle size and LA concentration, as both smaller and larger needle sizes, and low and high concentrations of LAs, led to myotoxicity. 
Discussion
Concerns have arisen after a recent case series reported presumed myotoxicity after lower-extremity nerve blocks, particularly adductor canal block. Although not biopsy proven, the clinical, electrophysiological, and imaging presentation of these cases is consistent with animal and ophthalmic models of LA-induced myotoxicity. The increasing popularity of adductor canal block and the uncertainty of whether myotoxicity is confined to this block only may have a potential impact on regional anaesthesia practice. By summarising the evidence on LA-induced myotoxicity from animal and human studies, our review helps identify the underlying mechanisms, enhance awareness, and analyse the potential implications.
The overarching results of our systematic review indicate that LAs used in clinical concentrations induce myotoxic damage in in vitro, ex vivo, in vivo, and human studies. Put into perspective, LA-induced myotoxicity is common in experimental animal studies and less common in human ocular blocks. The recent signal of presumed LA-induced myotoxicity after continuous adductor canal block makes this a less understood, but potentially serious complication. The damage observed in muscles after LA exposure was most pronounced in studies utilising myoblastic/myocytic cell lines and animal models. The clinically relevant LAs associated with myotoxicity included, in an increasing order of toxicity, lidocaine, demonstrated myotoxic effects, regardless of needle gauge, when administering clinically relevant LA concentrations. Furthermore, the majority of subjects in ophthalmic studies in whom myotoxic symptoms were observed reported no or slow partial recovery, and often required surgical, mechanical, or rehabilatory intervention to return to near baseline function. 4,5,7,88e99,101,107e110,113,114 Despite the obvious challenges of translating the analogous observations of in vivo, in vitro, and ex vivo studies into clinically meaningful findings, this systematic review of all levels of evidence demonstrates that myotoxicity is an important complication of LA administration that can compromise muscle function for extended periods of time. Translating this evidence into regional anaesthesia practice is more challenging; the paucity of evidence examining this complication precludes swift generalisation, although the signal observed with adductor canal block is certainly concerning.
Uniqueness of adductor canal block
It is unclear why the adductor canal block in specific, amongst all other truncal, upper-and lower-extremity nerve blocks, is associated with a risk of myotoxicity. In fact, despite our exhaustive review of the evidence for all regional anaesthesia techniques, and more than two decades of clinical experience with other lower-extremity regional anaesthesia techniques, such as femoral 122 and sciatic 123 blocks, there were no reports associating these blocks with myotoxicity. Furthermore, whilst factors related to high LA concentrations and prolonged exposure may offer potential explanations, we were unable to extrapolate these to the adductor canal block. For example, the report of myotoxicity after interscalene block 6 utilised unusually high doses of bupivacaine that are not relevant in today's practice (1140 mg over 36 h). Similarly, Bier block 87 uses LA doses calculated based on total body weight and also uses a tourniquet to restrict circulatory flow in the upper extremity; thus, vessels supply skeletal muscles with relatively high LA concentrations for the duration of surgery. Likewise, ophthalmic blocks involve the deposition of LAs in retro-or peribulbar fat within the confined orbital cavity, which may increase the intra-orbital pressure and transiently compromise ophthalmic blood vessel flow, 124 underscoring the two aforementioned factors.
Recognition
Whether an under-reported adverse event of LA exposure or truly an uncommon occurrence, myotoxicity seems to be both an overlooked and underrated regional anaesthesia complication in humans. Our systematic review suggests that approximately 0.53% (or 1 in 180) and 0.11% (or 1 in 800) of patients receiving ophthalmic blocks and adductor canal block, respectively, experience symptoms of myotoxicity. This rate may be even higher; it is plausible that reported cases of 'delayed onset motor weakness' following regional anaesthesia techniques 125, 126 may also have been precipitated by myotoxicity. Indeed, in a retrospective review of upper leg MRI obtained within a week of total knee arthroplasty performed on patients who had received a continuous adductor canal block, several patients had imaging and clinical presentation consistent with (undiagnosed) LAinduced myotoxicity (unpublished data, J.M.N.). Several anatomical, functional, and clinical reasons may account for these adverse events being overlooked. First, myotoxic changes may remain subclinical, and not manifest any significant symptoms. Second, flexor and extensor skeletal muscles generally function either in synchrony or in opposition to achieve a desired movement. Because of this, the inflammation or dysfunction of one specific muscle may not be recognised as a result of compensation by other agonists/ antagonistic muscles that perform complimentary functions. 127, 128 In contrast, eye muscles constitute a unique example because of little or no redundancy in muscle function. 129 This limited safety margin makes impairments to individual ocular muscles noticeable, particularly their visual manifestations. Third, the acute surgery-related inflammatory response 130 and accompanying weakness may conceal myotoxicity. However, as our results suggest, the clinical presentation of myotoxicity after adductor canal block has been that of acute onset flaccid weakness 1 or 2 days after surgery and initially effective physiotherapy, accompanied by radiological evidence of myositis at a site distant from the surgery. 7, 121 This unique temporal, spatial, and symptomatic presentation undermines the possibility of surgery-related weakness. Fourth, failure to detect myotoxic complications may be attributed to limited patient follow-up beyond the immediate postoperative period. 131, 132 In practice, more than one of these scenarios may explain underdetection. For example, LA is deposited between scalene muscles during an interscalene block, and myotoxicity may adversely affect the motor function of the sternocleidomastoid, and the anterior and middle scalene muscles. However, myotoxicity may remain undetected because (i) practitioners do not routinely perform quantitative motor strength assessments of ipsilateral neck flexors a few days after the block; (ii) neck flexors include complimentary muscles (e.g. longus coli and longus capitis); and (iii) motor weakness, if present, is likely subclinical.
Prevention
Based on the findings of this review, some clinical practice modifications may be considered to reduce the risk and severity of myotoxicity. These modifications are clearly not evidence-based recommendations, as our knowledge of this complication is still too sparse. First, limiting the use of bupivacaine, the LA observed to have the highest risk of myotoxicity, and the most severe symptoms amongst those examined, may be one strategy. Second, whilst myotoxicity is observed with all concentrations, practitioners may want to limit the use of LA concentrations higher than bupivacaine 0.375% and ropivacaine 0.5% in nerve blocks because of the possibility of myotoxic effects associated with these concentrations, as found in animal and ophthalmic studies. Third, based on animal studies, practitioners may want to consider limiting the duration of LA exposure by reconsidering the use of continuous peripheral nerve blocks and using other alternatives for prolonging block duration. 133e135 Whilst the reports about myotoxicity with adductor canal block catheters in knee arthroplasty patients and with femoral catheters in animal studies 74, 75 signal that the use of catheter-based LA infusions for 24e48 h may increase the risk of myotoxicity, 7, 121 it is not possible to exclude the initial LA bolus as a triggering cause. Obviously, the clinical, logistic, and even financial implications of such strategies have to be carefully examined against the ramifications of the progressive and perhaps eventual recognition of myotoxicity as a complication of regional anaesthesia.
Management
Myotoxicity may be difficult to identify after limb procedures, as the symptoms may be non-specific in nature and may be obscured by surgery-induced weakness. However, clinicians need to be diligent about the development of this adverse event if symptoms related to muscle/motor weakness and tenderness continue to persist beyond the expected regional anaesthesia recovery time, and in an anatomical distribution that is not commensurate with the surgical intervention. Regardless of the type of surgery, the diagnosis of myotoxicity can be difficult to make based on clinical symptomatology alone. Thus, systematic surveillance of such a complication may be prudent. High suspicion of this complication should prompt further laboratory testing and imaging. Studies have consistently shown that serum CPK, 8, 61 and occasionally glutamate concentrations, 82 appear to be persistently elevated after myotoxic damage. Whilst its diagnostic sensitivity and specificity have not been determined, MRI without contrast has been reported useful in diagnosis, with short T1 inversion recovery and T2-weighted images being findings indicative of myositis. 6, 109 Additional EMG studies are not commonly used, but are useful in identifying decreased polyphasic motor unit action potentials characteristic of myopathy, whilst myositis can be definitively diagnosed by muscle biopsy. 6, 7, 44 For ocular complaints, an ophthalmic exam is usually helpful in identifying paresis and contracture of the muscles surrounding the area of LA injection. 89 
Future research directions
Our results may have bearing on future research towards mitigating the myotoxic effects of LAs. Research should continue to focus on examining the role that LA adjuvants 136, 137 can play in reducing the degree of inflammatory changes. For example, studies have shown that both 1.5 ml, 97 3 ml, 89 4 ml, 92,94 6 ml, 91 9 ml, 91 5 ml, 89 14 ml, 89 0.2e0.5 ml, 103 3e10 ml, 100 4e6 ml, 4 5e10 ml, 92 4.5e9 ml 101 Diplopia, 4 113 5.5 ml, 92 6 ml, 91 7 ml, 4 8 ml, 91 9 ml, 101 10 ml, 91 17 ml, 89 3e10 ml, 100 5e10 ml 109, 112 Diplopia, 4 LA-induced myotoxicity in regional anaesthesia -835 dexamethasone 138 and dexmedetomidine 139, 140 exert antiinflammatory effects, whilst also prolonging block duration. However, they may also decrease clearance of LAs, thus prolonging exposure, and their effect on myotoxicity has not been investigated, 134, 141 as such future pharmacodynamic studies examining the effects of additives on myotoxicity are needed. As highlighted in our review, the retrobulbar block may offer an ideal experimental condition to determine the safest combinations of LAs and adjuvants. Future research should also evaluate the clinical relevance of the myotoxic effects associated with liposomal and microsphere formulation that were observed in animal studies. 19, 26, 58, 71, 72 Similarly, future research should examine the myotoxic risks associated with LA infiltration techniques, as the current evidence suggests a risk of myotoxicity equally significant to nerve blocks. As for continuous adductor canal block in specific, identifying the intrinsic causes that distinguish this block from others (e.g. continuous femoral block) 142 in terms of myotoxicity risk and render it clinically apparent is a priority. Factors that need to be explored include, but are not limited to, catheter location, type and concentration of LAs used, role of initial bolus dose, duration of infusion, effect of fascial planes, and the possible role of tourniquet pressure. The uncommon nature of this complication makes it less amenable to the conventional clinical trial design. 143 Longitudinal studies that rely on an objective assessment of motor power for screening, MRI imaging for confirmation, and biopsy for definitive diagnosis may be a suitable approach; these should be followed by studies of preventive and therapeutic strategies. Studies identifying the perioperative radiological and enzymatic variation patterns in knee arthroplasty patients are also needed.
Empirical analysis of probable implications
With clear reservations regarding the generalisation of concurrent evidence from animal and ophthalmic evidence, and a worrisome signal from the adductor canal block, into routine clinical practice, the potential implications of our findings may be empirically analysed.
Evidence from animal studies suggests that the risk of myotoxicity may be reduced by selecting perineural rather than inter-fascial or wound-infiltration interventions, using lower volumes and optimised concentrations, and reducing the duration of continuous infusion. Prolonged exposure, as a risk factor, has implications on the use of continuous blocks and continuous wound-infiltration techniques. In contrast, it seems intuitive that a single perineural injection delivering optimised concentrations and volumes of LAs mixed with adjuvants may entail less myotoxic effects compared with a catheter-based infusion that expands and prolongs the contact between LAs and muscles. Adjuvant enthusiasts may combine this concern with the training, logistic, and cost requirements of catheters, and their relatively high rates of leak and dislodgement, 144 to promote adjuvants as the ideal option for choice for block prolongation. However, it may be premature to blame exclusively the continuous adductor canal block for myotoxicity, as all reported cases combined an initial bolus with a subsequent infusion. It also remains to be elucidated whether risk-modification strategies may help safeguard against myotoxicity and sustain the continuous block practice.
In addition, it also appears that injection along myofascial planes is associated with significant myotoxic effects and a disruption of these fascial planes. 
Strengths and limitations
Our systematic review comes with several strengths that are worth noting. First, because of our extensive literature search, we incorporated non-English studies in this review. We were also able to comprehensively summarise and include the evidence from a large quantity and breadth of published literature on myotoxicity across all different study designs. This allowed us to provide key insights into the mechanisms and extent of damage observed with LA-induced myotoxicity that may have previously been unknown. Finally, whilst our review was qualitative in nature, we provided point-prevalence estimates for myotoxicity, its common symptoms, and the extent/nature of recovery. In contrast, our review has some limitations. Because of the nature of the topic, a considerable portion of the evidence reviewed was derived from in vitro and in vivo study designs. Although human studies provided considerable evidence of myotoxicity after limb and ophthalmic procedures, animal study designs do not necessarily reproduce in clinical settings and can be inherently difficult to translate into clinical practice. This can specifically be seen with the inclusion of studies evaluating the effects of LAs on myoblasts, as these cells are immature and do not express the RyR that is seen in skeletal muscles. 149 Most of the human literature on the topic was also in the form of case studies and case series; both designs lack the methodological and design rigor of clinical trials, and are limited by their descriptive nature smaller sample sizes. Furthermore, even though retrospective and prospective studies were included, these study designs were also limited by their lack of randomisation, blinding, and power analysis. Moreover, the point-prevalence estimates for LA-induced myotoxicity provided in our results should be used conservatively, as many studies included in this point estimate originated from ophthalmologic literature, calling for cautious generalisability. Finally, whilst the empirical analysis of implications on clinical practice depended on our observations in the evidence reviewed, it remains hypothetical and requires future supporting research.
In conclusion, skeletal muscles exposed to LAs consistently display myotoxic effects across experimental studies, with few concerning cases seen in human studies. The severity of damage appears to correlate with the type, concentration, and duration of exposure to LAs. The evidence is robust in animal and ophthalmic studies, with a concerning signal associated with continuous adductor canal block. The myotoxic effects seem to be clinically relevant, can be transient or permanent, and often require corrective interventions. As our understanding of the topic continues to grow, future practice may bring more emphasis to acknowledging myotoxicity as a complication of regional anaesthesia, particularly when disclosing the associated risks, providing immediate postoperative precautions, surveilling these patients for development of myotoxicity symptoms, and following-up symptomatic patients for management until resolution. The results of this systematic review should be advanced through sound clinical evidence to continue to further our understanding of LAinduced myotoxicity and to evolve regional anaesthetic practice towards reducing the risks of this complication. 
